Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
4.120
-0.400 (-8.85%)
At close: Oct 8, 2025, 4:00 PM EDT
4.190
+0.070 (1.70%)
After-hours: Oct 8, 2025, 6:39 PM EDT
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,551,706
Market Cap
2.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | 0 | - |
| Dec 31, 2023 | 2 | -10 | -83.33% |
| Dec 31, 2022 | 12 | -4 | -25.00% |
| Dec 31, 2021 | 16 | 7 | 77.78% |
| Dec 31, 2020 | 9 | 1 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLRX News
- 4 weeks ago - Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 7 weeks ago - Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewsWire
- 6 months ago - Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - GlobeNewsWire
- 7 months ago - Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers - GlobeNewsWire
- 9 months ago - Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga